Fujifilm Pharma

Jump to

Biosimilars to lead growth; generics to be a small part: Biocon

Biotechnology major Biocon reported 19.8 percent rise in revenue to Rs 796.2 crore year-on-year and margins grew to 25.2 percent from 21.2 percent in the second quarter of FY17. The company‘s standalones sale grew 17 percent in Q2.
Biocon surges 4%, launches diabetic drug in Japan

The company's partner FUJIFILM Pharma has launched Insulin Glargine in Japan, for which it had received Japanese regulator approval in last quarter.
US, Europe filings to drive Biocon growth: Kiran Mazumdar-Shaw

These market filings have a market opportunity of USD 40 billion. In particular, Japan offers a market potential of USD 150 million for its insulin product Glargine, says Biocon's Chairman and Managing Director.
Realisations from insulin biosimilar to start from FY17: Biocon

Getting approval to sell the biosimilar drug Glargine in Japan will open doors for the company, feels Kiran Mazumdar Shaw, Chairperson and Managing Director of Biocon.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Fujifilm Pharma

Biosimilars to lead growth; generics to be a small part: Biocon

Biocon surges 4%, launches diabetic drug in Japan

US, Europe filings to drive Biocon growth: Kiran Mazumdar-Shaw

Realisations from insulin biosimilar to start from FY17: Biocon